Sotrovimab News and Research

RSS

Challenges, unmet needs and future opportunities in COVID-19 therapeutics

In a recent article published in the journal Proceedings of the National Academy of Sciences (PNAS), researchers reviewed the present-day therapeutic landscape of coronavirus disease 2019 (COVID-19) and addressed future opportunities to overcome challenges that hinder drug development and improve the global preparedness for future pandemics.

10 Apr 2022

Study explores the antibody evasion pattern of SARS-CoV-2 Omicron sublineages

...

8 Apr 2022

SARS-CoV-2 Delta-Omicron recombinant identified in a transplant patient treated with Sotrovimab

Researchers described a case of co-infection with SARS-CoV-2 variants of concern, Delta and Omicron.

8 Apr 2022

Sotrovimab found to prevent hospitalization and mortality in COVID-19 outpatients

Researchers tested the efficacy of sotrovimab in non-hospitalized patients with SARS-CoV-2 infection.

7 Apr 2022

Researchers identify novel SARS-CoV-2 Delta-Omicron recombinant strain in Europe

A new study presented the rapid profiling of a SARS-CoV-2 Delta-Omicron recombinant sequence from Europe.

6 Apr 2022

ACE2 decoy receptor with robust neutralization against Omicron subvariants shows therapeutic potential

Researchers demonstrated the inhalation of an ACE2 decoy receptor, sACE22.v2.4-IgG1, increases survival and ameliorates lung injury in K18-hACE2 transgenic mice.

30 Mar 2022

Neutralization of BA.1 and BA.2 Omicron variants with monoclonal antibodies

A new research paper published as an early release manuscript in the Nature Medicine journal compares the sensitivity of this strain as well as the earlier Delta and the newer BA.2 to therapeutic mAbs.

27 Mar 2022

Monoclonal antibodies found to prevent lung inflammation in SARS-CoV-2-Omicron-infected mice

Researchers investigated how monoclonal antibodies, S309 and AZD7442, reduced lung infection in mice infected with the SARS-CoV-2 new variant of concern Omicron's BA.1, BA.1.1, and BA.2 sublineages.

23 Mar 2022

Novel monoclonal antibody found to have substantial neutralizing capacity against SARS-CoV-2 Omicron variant

Researchers reported a new monoclonal antibody, P2G3, which significantly neutralized the SARS-CoV-2 Omicron variant.

23 Mar 2022

Early treatment of COVID-19 in high-risk children and adolescents infected with the Omicron variant of SARS-CoV-2

Researchers discussed patient features, treatment-associated process measures, and outcomes associated with early monoclonal antibody and antiviral therapy in high-risk pediatric patients infected with the SARS-CoV-2 Omicron variant.

22 Mar 2022

Study explores SARS-CoV-2 spike epitope with potent and broad neutralization

Researchers reported an epitope with high potency and breadth and demonstrated that a therapeutic antibody directed at this site neutralizes all SARS-CoV-2 variants.

18 Mar 2022

Researchers evaluate predictors for mortality in hospitalized COVID-19 patients

Researchers identified independent factors associated with early and late deaths in hospitalized COVID-19 patients.

17 Mar 2022

The effects of anti-SARS-CoV-2 monoclonal antibodies on pregnant and postpartum women

Researchers examine the safety and efficacy of mAbs in pregnant and postpartum women with COVID-19.

16 Mar 2022

Neutralizing activity of therapeutic antibodies against clinical strains of BA.1 and BA.2 sub-lineages of the Omicron variant

Researchers conducted an in vitro analysis to assess the efficacy of monoclonal antibodies against the SARS-CoV-2 Omicron BA.2 and BA.1 variants.

14 Mar 2022

Sotrovimab News and Research

Challenges, unmet needs and future opportunities in COVID-19 therapeutics

Study explores the antibody evasion pattern of SARS-CoV-2 Omicron sublineages

SARS-CoV-2 Delta-Omicron recombinant identified in a transplant patient treated with Sotrovimab

Sotrovimab found to prevent hospitalization and mortality in COVID-19 outpatients

Researchers identify novel SARS-CoV-2 Delta-Omicron recombinant strain in Europe

ACE2 decoy receptor with robust neutralization against Omicron subvariants shows therapeutic potential

Neutralization of BA.1 and BA.2 Omicron variants with monoclonal antibodies

Monoclonal antibodies found to prevent lung inflammation in SARS-CoV-2-Omicron-infected mice

Novel monoclonal antibody found to have substantial neutralizing capacity against SARS-CoV-2 Omicron variant

Early treatment of COVID-19 in high-risk children and adolescents infected with the Omicron variant of SARS-CoV-2

Study explores SARS-CoV-2 spike epitope with potent and broad neutralization

Researchers evaluate predictors for mortality in hospitalized COVID-19 patients

The effects of anti-SARS-CoV-2 monoclonal antibodies on pregnant and postpartum women

Neutralizing activity of therapeutic antibodies against clinical strains of BA.1 and BA.2 sub-lineages of the Omicron variant

Clinical outcomes of regdanvimab usage in patients with mild to moderate COVID-19

8G3 broad-spectrum antibody effective against all SARS-CoV-2 variants, including Omicron

WHO experts suggest antiviral drug for patients with non-severe covid-19 at highest risk of hospitalization

Molecular characteristics of SARS-CoV-2 variants enabling antibody escape

The ability of therapeutic monoclonal antibodies to neutralize SARS-CoV-2 Omicron BA.2 variant

Research identifies differences between Omicron lineages BA.1 and BA.2

Unlocking the Secrets of Multiple Sclerosis Progression: Brain-Immune Cell Communication

Passing on Polycystic Ovary Syndrome: Health risks for male offspring of women with PCOS

Top-Down Proteomics: Bridging the Genotype-to-Phenotype Gap

Latest News